Development and test-retest reliability of a new, self-report questionnaire assessing healthcare use and personal costs in people with inflammatory bowel disease: the Inflammatory Bowel Disease Resource Use Questionnaire (IBD-RUQ).
COST-EFFECTIVENESS
CROHN'S DISEASE
HEALTH ECONOMICS
IBD
ULCERATIVE COLITIS
Journal
Frontline gastroenterology
ISSN: 2041-4137
Titre abrégé: Frontline Gastroenterol
Pays: England
ID NLM: 101528589
Informations de publication
Date de publication:
2023
2023
Historique:
received:
29
03
2022
accepted:
07
07
2022
entrez:
23
12
2022
pubmed:
24
12
2022
medline:
24
12
2022
Statut:
epublish
Résumé
The increasing prevalence of inflammatory bowel disease (IBD) poses a substantial economic burden globally on health systems and societies. Validated instruments to collect data on healthcare and other service utilisation by patients with IBD are lacking. We developed a self-report patient questionnaire to capture key resource utilisation from health services, patient and societal perspectives. The IBD Resource Use Questionnaire (IBD-RUQ), developed by a multidisciplinary team, including patients, comprises 102 items across the six categories of outpatient visits, diagnostics, medication, hospitalisations, employment and out-of-pocket expenses over the past three months. The test-retest reliability of the IBD-RUQ was studied by administering it twice among patients with IBD with a 2-week time gap. The intraclass correlation coefficients and the average cost from the healthcare, societal and patient perspectives, between test and retest assessments, overall and by service category, were summarised. The IBD-RUQ captures health service use, employment and out-of-pocket expenses. Of 55 patients who completed the first questionnaire, 48 completed the retest questionnaires and were included in the analyses. Test-retest reliability for categories of medications, diagnostics, specialist outpatient and inpatient services, and days off work due to IBD ranged from moderate to excellent; primary care visits showed more limited reliability. The annualised average self-reported health service, out-of-pocket and loss of productivity costs were £4844, £320 and £545 per patient, respectively. The IBD-RUQ is a reliable and valid self-report measure of resource utilisation in adults with IBD and can be used to measure costs associated with IBD.
Sections du résumé
Background and aims
UNASSIGNED
The increasing prevalence of inflammatory bowel disease (IBD) poses a substantial economic burden globally on health systems and societies. Validated instruments to collect data on healthcare and other service utilisation by patients with IBD are lacking. We developed a self-report patient questionnaire to capture key resource utilisation from health services, patient and societal perspectives.
Methods
UNASSIGNED
The IBD Resource Use Questionnaire (IBD-RUQ), developed by a multidisciplinary team, including patients, comprises 102 items across the six categories of outpatient visits, diagnostics, medication, hospitalisations, employment and out-of-pocket expenses over the past three months. The test-retest reliability of the IBD-RUQ was studied by administering it twice among patients with IBD with a 2-week time gap. The intraclass correlation coefficients and the average cost from the healthcare, societal and patient perspectives, between test and retest assessments, overall and by service category, were summarised.
Results
UNASSIGNED
The IBD-RUQ captures health service use, employment and out-of-pocket expenses. Of 55 patients who completed the first questionnaire, 48 completed the retest questionnaires and were included in the analyses. Test-retest reliability for categories of medications, diagnostics, specialist outpatient and inpatient services, and days off work due to IBD ranged from moderate to excellent; primary care visits showed more limited reliability. The annualised average self-reported health service, out-of-pocket and loss of productivity costs were £4844, £320 and £545 per patient, respectively.
Conclusions
UNASSIGNED
The IBD-RUQ is a reliable and valid self-report measure of resource utilisation in adults with IBD and can be used to measure costs associated with IBD.
Identifiants
pubmed: 36561790
doi: 10.1136/flgastro-2022-102182
pii: flgastro-2022-102182
pmc: PMC9763637
doi:
Types de publication
Journal Article
Langues
eng
Pagination
59-67Informations de copyright
© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: No.
Références
BMJ. 2000 Feb 26;320(7234):544-8
pubmed: 10688560
Clinicoecon Outcomes Res. 2012;4:209-18
pubmed: 22866007
PLoS One. 2016 Dec 16;11(12):e0168586
pubmed: 27992531
Am J Gastroenterol. 2004 Apr;99(4):650-5
pubmed: 15089897
Eur J Gastroenterol Hepatol. 2014 Feb;26(2):213-21
pubmed: 24145865
PLoS One. 2016 Apr 21;11(4):e0142481
pubmed: 27099937
Clin Ther. 2008 Feb;30(2):393-404
pubmed: 18343277
J Clin Epidemiol. 2000 Mar 1;53(3):297-306
pubmed: 10760641
J Med Econ. 2015 Jun;18(6):447-56
pubmed: 25728698
J Clin Epidemiol. 2017 Feb;82:167-172
pubmed: 27825891
Cochrane Database Syst Rev. 2009 Jul 08;(3):MR000008
pubmed: 19588449
Aliment Pharmacol Ther. 2020 May;51(10):922-934
pubmed: 32237083
Gut. 2004 Nov;53(11):1639-45
pubmed: 15479685
J Crohns Colitis. 2014 Jul;8(7):598-606
pubmed: 24345767
Gut. 1998 Jul;43(1):29-32
pubmed: 9771402
Gastroenterology. 2006 Sep;131(3):719-28
pubmed: 16952541
J Crohns Colitis. 2017 Mar 01;11(3):342-352
pubmed: 27647859
Scand J Gastroenterol. 2013 Jan;48(1):51-7
pubmed: 22577851
J Chiropr Med. 2016 Jun;15(2):155-63
pubmed: 27330520
Gut. 2004 Oct;53(10):1471-8
pubmed: 15361497
Lancet. 1980 Mar 8;1(8167):514
pubmed: 6102236
Frontline Gastroenterol. 2014 Jul;5(3):183-189
pubmed: 28839768
Eur J Gastroenterol Hepatol. 2002 Nov;14(11):1205-15
pubmed: 12439115
Inflamm Bowel Dis. 2016 Mar;22(3):688-93
pubmed: 26835981
Inflamm Bowel Dis. 2015 Jan;21(1):121-31
pubmed: 25437816
Pharmacoeconomics. 2021 Sep;39(9):983-993
pubmed: 34169466
Trials. 2015 Oct 06;16:444
pubmed: 26445224
Inflamm Bowel Dis. 2009 Dec;15(12):1882-90
pubmed: 19408336
J Pediatr Gastroenterol Nutr. 2002 Oct;35(4):557-63
pubmed: 12394384
Am J Gastroenterol. 2001 Dec;96(12):3329-36
pubmed: 11774945
Pharmacoeconomics. 2006;24(8):797-814
pubmed: 16898849
Gastroenterology. 2017 Feb;152(2):313-321.e2
pubmed: 27793607
Inflamm Bowel Dis. 2014 Apr;20(4):637-45
pubmed: 24518606
Public Health Nutr. 2019 Apr;22(6):967-975
pubmed: 30761972